BMAC injection: What practices need to know

Key takeaways

A BMAC injection concentrates stem cells and growth factors from a patient’s own bone marrow to repair damaged joints, tendons, and bones.

The procedure takes 60 to 90 minutes, and most patients return to light activity within a few days.

Evidence is strongest for knee osteoarthritis, rotator cuff tears, and non-union fractures.

Expect $3,000 to $5,000 per session in the US and £2,000 to £5,000 in the UK, rarely covered by insurance.

BMAC carries a higher concentration of mesenchymal stem cells than PRP, which suits more advanced tissue damage.

Download BMAC Injection Patient Assessment worksheet

Download this free BMAC injection patient assessment worksheet. Screen candidates, document the procedure, and track outcomes with structured follow-up fields.

Download worksheet

About 33 million US adults live with osteoarthritis, according to the CDC. Most cycle through cortisone shots, hyaluronic acid, and physical therapy long before joint replacement is on the table. BMAC injection has captured patient attention in that stretch of the treatment ladder.

The procedure draws a small bone marrow sample from the iliac crest and spins it down in a centrifuge. That concentrates mesenchymal stem cells, platelets, and growth factors, which go straight into the damaged tissue.

Patient-facing explainers stop at the biology. A practice also has to run the service, which means screening candidates, pricing the session, and tracking outcomes over years rather than weeks. This guide covers that side.

What is a BMAC injection?

A BMAC injection is concentrated bone marrow, delivered into damaged tissue. The clinician harvests a small marrow sample, spins it in a centrifuge, and injects the concentrate. Bone marrow carries mesenchymal stem cells (MSCs), platelets, cytokines, and growth factors that drive tissue regeneration.

The science rests on the body’s own repair mechanisms. MSCs can differentiate into bone, cartilage, and connective tissue cells. Concentrated and delivered to an injury site, they stimulate a localized healing response.

Research published in Scientific Reports (2024) followed knee osteoarthritis patients for four years after treatment. Pain scores and joint function had both improved significantly at that four-year mark.

BMAC is autologous, so the concentrate comes from the patient’s own body. That removes the risk of immune rejection, which gives you a safer treatment profile and fewer adverse reactions to manage.

How the BMAC injection procedure works

Knowing the sequence helps you set accurate patient expectations and block the right amount of chair time.

Step 1: Patient assessment and preparation

The clinician reviews the patient’s medical history, current medications, and imaging. Blood disorders, active infections, and certain cancers may disqualify a candidate. Patients typically stop anti-inflammatory medications five to seven days before the procedure.

Step 2: Bone marrow aspiration

Under local anesthesia, the practitioner inserts a specialized needle into the posterior iliac crest, at the back of the hip bone. A syringe draws out 30 to 60 milliliters of bone marrow aspirate. That takes roughly 10 to 15 minutes.

Step 3: Centrifugation and concentration

The aspirate goes into a centrifuge and spins at high speed for 15 to 20 minutes. This separates the sample into layers and isolates the buffy coat, which is rich in MSCs, platelets, and growth factors. The final concentrate runs five to seven times stronger than the original aspirate.

Step 4: Injection into the target site

The concentrate goes directly into the damaged tissue under ultrasound or fluoroscopic guidance. Image guidance keeps placement precise, which improves outcomes and lowers the risk of complications.

Conditions treated with BMAC injection

BMAC has clinical applications across orthopedics, sports medicine, and emerging aesthetic fields.

Joint conditions

Knee osteoarthritis is the most researched application. A 2024 systematic review of randomized controlled trials found clinical improvements in pain and function for knee osteoarthritis patients. The same review found no significant difference between BMAC and hyaluronic acid on function scores at 3, 6, or 12 months. Its authors called for more research on where BMAC sits against other intra-articular options. Hip and ankle osteoarthritis also respond to treatment.

Tendon and ligament injuries

Rotator cuff tears, Achilles tendinopathy, and lateral epicondylitis (tennis elbow) are common targets. The growth factors in BMAC promote collagen synthesis and speed tendon repair. Sports medicine practices usually pair the injection with a phased loading program rather than rest alone.

Bone healing

Non-union fractures and bone defects benefit from the osteogenic potential of MSCs. Orthopedic surgeons sometimes use BMAC during surgical bone grafting to improve fusion rates.

Emerging aesthetic applications

Some practices now offer BMAC for facial rejuvenation and hair restoration. The high concentration of growth factors may stimulate collagen production and hair follicle regeneration. Evidence in aesthetics stays preliminary next to the orthopedic literature, so keep the claims conservative.

Who is a good candidate for BMAC injection?

Patients with mild to moderate osteoarthritis, Kellgren-Lawrence grades I to III, respond best. Those with severe end-stage arthritis may still benefit, though expectations need adjusting. Younger patients with acute sports injuries also do well, because their baseline stem cell counts are higher.

Contraindications include active bone marrow disorders, blood cancers, uncontrolled infections, and bleeding disorders. Patients on blood thinners may need to pause them under medical supervision before the procedure.

Screening protects the patient and the practice in equal measure. A standardized intake questionnaire is what stops a critical piece of history going unrecorded at the assessment stage.

Benefits and risks of BMAC therapy

Benefits

• Autologous source. Using the patient’s own cells removes rejection risk and allergic reactions.
• Minimally invasive. The whole procedure happens in an office setting without general anesthesia.
• Short recovery. Most patients resume normal activities within one to two weeks.
• Durable results. Studies show sustained improvement two to four years after injection.
• Broad application. It treats joints, tendons, bones, and soft tissue injuries.

Risks

• Bruising, swelling, or soreness at the aspiration and injection sites, common and resolving within days.
• Infection at the needle insertion point, rare with proper sterile technique.
• Nerve or blood vessel damage during aspiration, uncommon with experienced practitioners.
• Variable outcomes, depending on patient age, health status, and severity of the condition.

Document every one of these through a standardized consent process. Keep the signed version in the patient’s record alongside the procedure note, so the file tells the whole story later.

Recovery and what to expect

Patients typically leave within an hour of the procedure. Downtime is short, but the therapeutic effect arrives late, and that mismatch is where expectations usually go wrong.

• Days 1 to 3: Mild to moderate soreness at both the aspiration and injection sites. Ice and acetaminophen manage the discomfort.
• Days 3 to 7: Swelling subsides. Light walking and daily activities resume.
• Weeks 2 to 4: Gradual return to exercise and physical demands. Avoid high-impact activities.
• Weeks 6 to 12: Full therapeutic effects begin to show as tissue regeneration progresses.

Put the procedure day and the recovery arc on one axis and the shape of the treatment becomes obvious.

Send the recovery instructions at each of those points rather than all at once on discharge. Patients read them when they apply, which cuts the number of calls your front desk fields at week two.

Cost considerations for BMAC injection

BMAC is a premium regenerative treatment. In the US, a session runs $3,000 to $5,000. In the UK, prices generally sit between £2,000 and £5,000. Several factors move the number:

• Location and overheads. Practices in major metro areas charge more.
• Imaging guidance. Ultrasound-guided injections add to the cost.
• Number of injection sites. Treating multiple joints raises the total fee.
• Follow-up care. Some practices bundle post-procedure consultations into the price.

Most private insurance plans and the NHS do not cover BMAC, because regulators still classify it as investigational for many indications. That makes it a self-pay line, so payment plans and clear pricing at consultation matter more than they would for a covered procedure.

The global BMAC market stood at $208.63 million in 2025 and is projected to reach $297.61 million by 2031, a 6.12% CAGR (Mordor Intelligence). Growth is steady rather than sharp, which matters if you are sizing the investment.

BMAC vs PRP vs stem cell therapy

Patients ask how the three compare, usually after reading about all of them in one sitting. Price is the first thing they notice, and the three options are not close.

Cost is only one axis. Here is how the three differ on source, contents, and the cases they suit.

An opinion paper in Frontiers in Medicine (2024) reviewed multiple meta-analyses of the two treatments. It concluded that BMAC outcomes are at least equivalent to PRP at one-year follow-up, with BMAC’s advantage becoming clinically relevant from year two. BMAC showed more promise in severe cases, which its stem cell content would predict.

Many sports medicine practices now run both, matched to the severity in front of them. Some also offer amniotic injection therapy as an off-the-shelf regenerative option that skips the marrow draw.

Adding BMAC to your treatment menu

A BMAC service needs more than a centrifuge. Five things decide whether it runs cleanly:

• Staff training. Practitioners need qualifications in regenerative medicine and ultrasound-guided injection technique.
• Equipment. Budget for a quality centrifuge system, aspiration kits, and imaging.
• Documentation. Standardize consent, medical history, and procedure notes before the first booking.
• Patient communication. Set expectations at consultation, then hold the same line at every follow-up.
• Compliance. Follow the regenerative medicine rules for your jurisdiction, which vary by state in the US.

If you already run PRP, your existing paperwork gets you most of the way there. A PRP consent form covers the same autologous-biologic ground and adapts with a new procedure description and risk list.

Building patient confidence in BMAC services

Patients arrive having read about stem cells online, and some of what they read overstates the case. Correcting that at consultation is part of the job.

Practices that give clear, evidence-based information convert more inquiries into bookings. Share published outcomes, walk through the timeline visually, and hand over written aftercare the patient can read at home.

Tracking outcomes over time is what lets you make claims you can defend. Log pain scores, functional improvement, and satisfaction across your BMAC cohort with measurements tracking software. Then let the numbers shape the protocol.

How Pabau supports BMAC screening, documentation, and outcomes

Most practices run a BMAC service across three or four disconnected systems. Screening sits in a paper questionnaire, consent in a PDF, pain scores in a spreadsheet, and aftercare with whoever remembers to send it.

Practice management software like Pabau keeps all four in one patient record. Pabau is software for longevity practices, so a BMAC pathway is a supported workflow rather than a workaround. Digital intake forms capture the screening questions and contraindications before the appointment is confirmed. Consent is signed on screen and filed against the procedure note.

Pain and function scores go in as structured fields, so you can chart a cohort instead of digging through notes. Every subscription includes that reporting. Insights Plus, an additional reporting add-on, goes further for practices that want to segment by indication or practitioner.

A practice running BMAC alongside PRP or IV therapy has the same problem several times over. A regenerative medicine EMR puts the protocols, consent versions, and outcome fields for each line in the same place.

One record for BMAC screening, consent, and outcomes

Pabau’s digital intake forms capture your BMAC screening questions and contraindications before the appointment is confirmed. Consent files against the procedure note, and pain and function scores go in as structured fields you can chart.

Book a demo

Conclusion

BMAC injection is a credible option at the top of the conservative care ladder. The evidence is strongest where tissue damage is moderate rather than end-stage, and the practices that do well with it say so plainly at consultation.

The trade-off worth remembering is the timing. Downtime ends in a week, but the therapeutic effect does not show until weeks six to twelve. A patient reviewed at week three will call the treatment a failure, so book the review where the data is.

That puts as much weight on the operational side as the clinical one. Screen candidates against written criteria, capture pain and function scores at fixed intervals, and file the consent version with the note. Book a demo to see how a regenerative medicine practice runs BMAC screening, consent, and outcome tracking in one record.

Continue your research

Comparing regenerative options? Amniotic injection therapy covers an off-the-shelf alternative that skips the marrow draw, and where it fits against BMAC.

Need consent paperwork you can adapt? Platelet rich plasma PRP consent gives you a signed-consent structure that transfers cleanly to a BMAC procedure.

Worried about overclaiming results? Interpreting biomarkers without overpromising shows how to talk about outcome data without promising more than the evidence supports.

Building out a regenerative menu? Ozone therapy protocol walks through the operational checks before adding another regenerative line to your treatment list.

Frequently asked questions